$PLX
Protalix BioTherapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837024015612 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $17.96M
YoY Change 73.6%
Cost Of Revenue $8.375M
YoY Change 71.16%
Gross Profit $9.584M
YoY Change 75.79%
Gross Profit Margin 53.37%
Selling, General & Admin $2.595M
YoY Change -29.29%
% of Gross Profit 27.08%
Research & Development $2.998M
YoY Change -18.29%
% of Gross Profit 31.28%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $5.593M
YoY Change -23.79%
Operating Profit $3.991M
YoY Change -311.5%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$148.0K
YoY Change -188.1%
Pretax Income $3.843M
YoY Change -323.56%
Income Tax $607.0K
% Of Pretax Income 15.79%
Net Earnings $3.236M
YoY Change -274.73%
Net Earnings / Revenue 18.02%
Basic Earnings Per Share $0.04
Diluted Earnings Per Share $0.03
COMMON SHARES
Basic Shares Outstanding 73.63M 73.54M
Diluted Shares Outstanding 81.22M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $27.41M
Short-Term Investments
Other Short-Term Assets $1.050M
YoY Change -6.67%
Inventory $17.20M
Prepaid Expenses
Receivables $2.195M
Other Receivables
Total Short-Term Assets $47.85M
YoY Change -34.1%
LONG-TERM ASSETS
Property, Plant & Equipment $4.648M
YoY Change -0.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $13.71M
YoY Change -8.3%
TOTAL ASSETS
Total Short-Term Assets $47.85M
Total Long-Term Assets $13.71M
Total Assets $61.56M
YoY Change -29.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.58M
YoY Change 4.47%
Accrued Expenses $8.342M
YoY Change -9.81%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.22M
YoY Change -44.14%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $4.906M
YoY Change -17.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.22M
Total Long-Term Liabilities $4.906M
Total Liabilities $29.13M
YoY Change -40.95%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $32.44M
YoY Change
Total Liabilities & Shareholders Equity $61.56M
YoY Change -29.7%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $3.236M
YoY Change -274.73%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001006281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33357
dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0643773
dei Entity Address Address Line1
EntityAddressAddressLine1
2 University Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Hackensack
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07601
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
696-9345
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
PLX
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
73633583
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27409000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23634000
CY2023Q4 plx Short Term Bank Deposits
ShortTermBankDeposits
20926000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2195000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5272000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1050000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1055000
CY2024Q3 us-gaap Inventory Net
InventoryNet
17199000
CY2023Q4 us-gaap Inventory Net
InventoryNet
19045000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
47853000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
69932000
CY2024Q3 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
561000
CY2023Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
528000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4648000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4973000
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2856000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3092000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5645000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5909000
CY2024Q3 us-gaap Assets
Assets
61563000
CY2023Q4 us-gaap Assets
Assets
84434000
CY2024Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
3135000
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4320000
CY2024Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
19577000
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
19550000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1508000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1409000
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
20251000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
24220000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
45530000
CY2024Q3 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
730000
CY2023Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
714000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4176000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4621000
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4906000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5335000
CY2024Q3 us-gaap Liabilities
Liabilities
29126000
CY2023Q4 us-gaap Liabilities
Liabilities
50865000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
32437000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
33569000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61563000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84434000
us-gaap Revenues
Revenues
35181000
us-gaap Revenues
Revenues
55008000
CY2024Q3 us-gaap Revenues
Revenues
17959000
CY2023Q3 us-gaap Revenues
Revenues
10345000
us-gaap Cost Of Revenue
CostOfRevenue
20433000
us-gaap Cost Of Revenue
CostOfRevenue
14126000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
8375000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
4893000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8846000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13991000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2998000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3669000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9194000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10816000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2595000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3670000
us-gaap Operating Income Loss
OperatingIncomeLoss
-3292000
us-gaap Operating Income Loss
OperatingIncomeLoss
16075000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3991000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1887000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1056000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2406000
CY2024Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
299000
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
460000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1186000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1323000
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
151000
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
628000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
130000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1083000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-148000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
168000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3162000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14992000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3843000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1719000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
636000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
607000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
133000
us-gaap Net Income Loss
NetIncomeLoss
-3562000
us-gaap Net Income Loss
NetIncomeLoss
14356000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
3236000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1852000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73301091
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65811506
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73549745
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72281681
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73301091
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81040281
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81217068
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83782679
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10640000
plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
23954000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
7783000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1195000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
887000
plx Stock Issued During Period Value Warrants Exercises
StockIssuedDuringPeriodValueWarrantsExercises
712000
us-gaap Net Income Loss
NetIncomeLoss
14356000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
38247000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
33569000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1191000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
1408000
us-gaap Net Income Loss
NetIncomeLoss
-3562000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
32437000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
39001000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
383000
CY2023Q3 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
715000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1852000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
38247000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
28581000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
358000
CY2024Q3 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
262000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
3236000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
32437000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
185000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
185000000
us-gaap Profit Loss
ProfitLoss
-3562000
us-gaap Profit Loss
ProfitLoss
14356000
us-gaap Share Based Compensation
ShareBasedCompensation
2599000
us-gaap Share Based Compensation
ShareBasedCompensation
2081000
us-gaap Depreciation
Depreciation
970000
us-gaap Depreciation
Depreciation
878000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-173000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
511000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
32000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
-50000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
236000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3092000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
20000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
49000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000
plx Gain Loss On Debt Conversion
GainLossOnDebtConversion
421000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
208000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-13178000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3069000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4188000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-13000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-12000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1846000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4779000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-670000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3820000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4683000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4913000
plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
20420000
plx Proceeds From Withdrawal Of Short Term Deposits
ProceedsFromWithdrawalOfShortTermDeposits
20420000
plx Proceeds From Withdrawal Of Short Term Deposits
ProceedsFromWithdrawalOfShortTermDeposits
5000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
857000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
899000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
25000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
50000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19541000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16369000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
20420000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23954000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
712000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-20420000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24666000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-29000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-87000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3775000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3297000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23634000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17111000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27409000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20408000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
402000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
253000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
376000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1395000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
7783000
us-gaap Interest Paid Net
InterestPaidNet
1532000
us-gaap Interest Paid Net
InterestPaidNet
2743000
plx Interest Received Net
InterestReceivedNet
1481000
plx Interest Received Net
InterestReceivedNet
303000
CY2024Q3 plx Number Of Global Licensing And Supply Agreements
NumberOfGlobalLicensingAndSupplyAgreements
2
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
20251000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
415045000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
381549000
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4242000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4176000
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
12251000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
9055000
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
706000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5814000
CY2024Q3 us-gaap Inventory Net
InventoryNet
17199000
CY2023Q4 us-gaap Inventory Net
InventoryNet
19045000
us-gaap Net Income Loss
NetIncomeLoss
-3562000
us-gaap Net Income Loss
NetIncomeLoss
14356000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
3236000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1852000
us-gaap Dilutive Securities
DilutiveSecurities
-1610000
CY2024Q3 us-gaap Dilutive Securities
DilutiveSecurities
-503000
CY2023Q3 us-gaap Dilutive Securities
DilutiveSecurities
-1766000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3562000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
12746000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2733000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3618000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73301091
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65811506
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73549745
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72281681
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
13981660
CY2024Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
7667323
CY2023Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
11500998
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1247115
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73301091
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81040281
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81217068
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83782679
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
164000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3728000
CY2024Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
164000
CY2023Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
95000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
236000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3092000
CY2024Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
443000
CY2023Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
38000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
636000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
607000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
133000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.13
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.04
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q2 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3100000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1251000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1437000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
511000
CY2024Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1713000
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1605000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8342000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9009000
CY2024Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
571000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
637000
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
3040000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
2876000
CY2024Q3 plx Reserve For Deductions From Revenue Current
ReserveForDeductionsFromRevenueCurrent
4258000
CY2023Q4 plx Reserve For Deductions From Revenue Current
ReserveForDeductionsFromRevenueCurrent
2861000
CY2024Q3 plx Accounts Payable Property And Equipment Suppliers Current
AccountsPayablePropertyAndEquipmentSuppliersCurrent
402000
CY2023Q4 plx Accounts Payable Property And Equipment Suppliers Current
AccountsPayablePropertyAndEquipmentSuppliersCurrent
614000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
19577000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
19550000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-015612-index-headers.html Edgar Link pending
0001558370-24-015612-index.html Edgar Link pending
0001558370-24-015612.txt Edgar Link pending
0001558370-24-015612-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plx-20240930.xsd Edgar Link pending
plx-20240930x10q.htm Edgar Link pending
plx-20240930x10q005.jpg Edgar Link pending
plx-20240930x10q007.jpg Edgar Link pending
plx-20240930x10q008.jpg Edgar Link pending
plx-20240930xex31d1.htm Edgar Link pending
plx-20240930xex31d2.htm Edgar Link pending
plx-20240930xex32d1.htm Edgar Link pending
plx-20240930xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
plx-20240930_cal.xml Edgar Link unprocessable
plx-20240930_def.xml Edgar Link unprocessable
plx-20240930_lab.xml Edgar Link unprocessable
plx-20240930_pre.xml Edgar Link unprocessable
plx-20240930x10q_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable